
1. Clin Res Hepatol Gastroenterol. 2015 Sep;39(4):443-50. doi:
10.1016/j.clinre.2014.12.007. Epub 2015 Jan 27.

Early virological assessment during telaprevir- or boceprevir-based triple
therapy in hepatitis C cirrhotic patients who failed a previous interferon based 
regimen - The ANRS CO20-CUPIC study.

Bailly F(1), Virlogeux V(2), Dufour C(3), Pradat P(1), Hézode C(4), Larrey D(5), 
Alric L(6), Samuel D(7), Bourlière M(8), Métivier S(9), Zarski JP(10), Fontaine
H(11), Loustaud-Ratti V(12), Serfaty L(13), Bronowicki JP(14), Carrat F(3),
Zoulim F(15); CUPIC Study Group.

Author information: 
(1)Department of Hepatology, Hôpital de la Croix-Rousse, Hospices Civils de Lyon,
69004 Lyon, France; Inserm U1052, 69003 Lyon, France; Université Lyon I, 69622
Villeurbanne, France.
(2)Department of Hepatology, Hôpital de la Croix-Rousse, Hospices Civils de Lyon,
69004 Lyon, France; École Normale Supérieure, 69007 Lyon, France.
(3)Inserm UMR-S 707, Université Pierre-et-Marie-Curie Paris 6, 75012 Paris,
France.
(4)Hépato-gastro-entérologie, CHU Henri-Mondor, 94010 Créteil, France.
(5)Hépato-gastroentérologie, CHU de Montpellier, Hôpital Saint-Éloi, 34090
Montpellier, France.
(6)Pôle Digestif, CHU Purpan, UMR 152, Université Toulouse 3, 31059 Toulouse,
France.
(7)Centre Hépato-Biliaire, AP-HP Hôpital Paul-Brousse, 94870 Villejuif, France;
Unité 785, Inserm, 94870 Villejuif, France; Université Paris-Sud, 94270 Le
Kremlin-Bicêtre, France.
(8)Department of Hepatology and Gastroenterology, Hôpital Saint-Joseph, 13285
Marseille, France.
(9)Pôle Digestif-Gastro-entérologie-Hépatologie, CHU Purpan, 31059 Toulouse,
France.
(10)Clinique universitaire d'Hépato-Gastroentérologie, CHRU Michallon, 38043
Grenoble, France.
(11)Hôpital Cochin, AP-HP, Université Paris-René Descartes, Inserm U1016, 75014
Paris, France.
(12)Fédération Hépatologie, CHU Dupuytren, 87042 Limoges, France.
(13)Hépato-gastro-entérologie orienté en hépatologie, CHU Saint-Antoine, 75012
Paris, France.
(14)Department of Hepatology and Gastroenterology, CHU de Nancy, Université de
Lorraine, Inserm U954, 54500 Vandœuvre-lès-Nancy, France.
(15)Department of Hepatology, Hôpital de la Croix-Rousse, Hospices Civils de
Lyon, 69004 Lyon, France; Inserm U1052, 69003 Lyon, France; Université Lyon I,
69622 Villeurbanne, France. Electronic address: fabien.zoulim@inserm.fr.

BACKGROUND AND OBJECTIVE: To assess within the ANRS CO20-CUPIC cohort whether the
viral load (VL) at week 2/week 6 for telaprevir/boceprevir-based triple therapy, 
respectively, was predictive of sustained virological response (SVR) in patients 
with hepatitis C virus (HCV) infection and to study the relevance of this
measurement to early diagnose drug resistance.
METHODS: Observational study of HCV genotype 1 patients with compensated
cirrhosis (Child-Pugh A), non-responders to a prior course of interferon
(IFN)-based therapy and who started triple therapy. Patients received either 12
weeks of telaprevir in combination with PEG-IFN/ribavirin (RBV), then 36 weeks of
PEG-IFN/RBV, or 4 weeks of PEG-IFN/RBV, then 44 weeks of PEG-IFN/RBV and
boceprevir.
RESULTS: A total of 262 patients were analyzed. For telaprevir-treated patients, 
28% had undetectable VL at W2 of whom 81% achieved SVR12 whereas 67% had
undetectable VL at W4 of whom 67% achieved SVR12. For boceprevir-treated patients
20% had undetectable VL at W6 and 86% of them achieved SVR12 whereas 36% had
undetectable VL at W8 among whom 73% achieved SVR12. Five telaprevir-treated
patients had a VL increase between W2 and W4 after a decrease between D0 and W2. 
Four of them did not achieve SVR12. Similarly, six boceprevir-treated patients
had a VL increase between W6 and W8 after a decrease between D0 and W6. Five did 
not reach SVR12.
CONCLUSIONS: The assessment of HCV RNA level after two weeks of triple therapy in
cirrhotic non-responder patients is a good predictor of SVR. This assessment was 
useful to do an early diagnosis of viral breakthrough.

Copyright © 2015 Elsevier Masson SAS. All rights reserved.

DOI: 10.1016/j.clinre.2014.12.007 
PMID: 25636238  [Indexed for MEDLINE]

